<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-sub-section" /><meta name="keywords" content="Corticosteroids: rheumatic disease; Prednisolone: rheumatic disease; Polymyalgia rheumatica; Arteritis, giant cell (temporal); Giant cell arteritis; Polyarteritis nodosa; Polymyositis; Lupus erythematosus: systemic" /><meta name="IX" content="Corticosteroids: rheumatic disease; Prednisolone: rheumatic disease; Polymyalgia rheumatica; Arteritis, giant cell (temporal); Giant cell arteritis; Polyarteritis nodosa; Polymyositis; Lupus erythematosus: systemic" /><title>10.1.2.1 Systemic corticosteroids: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="5270.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="5270.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=5270.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5269.htm">10.1.2 Corticosteroids</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5269.htm" title="Previous: 10.1.2 Corticosteroids">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="5272.htm" title="Next: 10.1.2.2 Local corticosteroid injections">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_5270">10.1.2.1 Systemic corticosteroids</h1><?highlighter on?><div id="pC" class="jN"><div><p>The general actions, uses, and cautions of <span>corticosteroids</span> are described in <a title=" Corticosteroids" href="4249.htm#_4249">section 6.3</a>. Short-term treatment with corticosteroids can
help to rapidly improve symptoms of rheumatoid arthritis. Long-term
treatment in rheumatoid arthritis should be considered only after
evaluating the risks and all other treatment options have been considered.
Corticosteroids can induce osteoporosis, and prophylaxis should be
considered on long-term treatment (<a title="section: Drugs affecting bone metabolism" href="4439.htm#_4439">section 6.6</a>).</p><p>In severe, possibly life-threatening, situations a high initial
dose of corticosteroid is given to induce remission and the dose is
then reduced gradually and discontinued altogether. Relapse may occur
as the dose of corticosteroid is reduced, particularly if the reduction
is too rapid. The tendency is therefore to increase the maintenance
dose and consequently the patient becomes dependent on corticosteroids.
For this reason pulse doses of corticosteroids (e.g. methylprednisolone
up to 1 g intravenously on 3 consecutive days) are used to suppress
highly active inflammatory disease while longer-term treatment with
a disease-modifying drug is commenced.</p><p><b><span>Prednisolone</span> </b>7.5 mg daily may
reduce the rate of joint destruction in moderate to severe <i>rheumatoid arthritis</i> of less than 2 years’ duration. The
reduction in joint destruction must be distinguished from mere symptomatic
improvement (which lasts only 6 to 12 months at this dose) and care
should be taken to avoid increasing the dose above 7.5 mg daily. Evidence
supports maintenance of this anti-erosive dose for 2–4 years only
after which treatment should be tapered off to reduce long-term adverse
effects.</p><p>A modified-release preparation of <b>prednisone</b> (<a title="BNF:monograph: PREDNISONE" href="203685.htm#_203685">section 6.3.2</a>) is also available for the treatment
of moderate to severe rheumatoid arthritis.</p><p><i>Polymyalgia rheumatica </i>and <i>giant cell (temporal) arteritis </i>are always treated with <span>corticosteroids</span>. The usual
initial dose of <span>prednisolone</span> in polymyalgia rheumatica
is 10–15 mg daily and in giant cell arteritis 40–60 mg daily (the
higher dose being used if visual symptoms occur). Treatment should
be continued until remission of disease activity and doses are then
reduced gradually to about 7.5 –10 mg daily for maintenance. Relapse
is common if therapy is stopped prematurely. Many patients require
treatment for at least 2 years and in some patients it may be necessary
to continue long-term low-dose corticosteroid treatment.</p><p><i>Polyarteritis nodosa </i>and <i>polymyositis </i>are usually treated with <span>corticosteroids</span>. An initial dose of 60 mg of <span>prednisolone</span> daily
is often used and reduced to a maintenance dose of 10–15 mg daily. </p><p><i>Systemic lupus erythematosus </i>is treated with <span>corticosteroids</span> when necessary using a similar dosage regimen
to that for polyarteritis nodosa and polymyositis (above). Patients
with pleurisy, pericarditis, or other systemic manifestations will
respond to <span>corticosteroids</span>. It may then be possible
to reduce the dosage; alternate-day treatment is sometimes adequate,
and the drug may be gradually withdrawn. In some mild cases corticosteroid
treatment may be stopped after a few months. Many mild cases of systemic
lupus erythematosus do not require corticosteroid treatment. Alternative
treatment with anti-inflammatory <span>analgesics</span>, and
possibly <span>chloroquine</span> or hydroxy<span>chloroquine</span>, should be considered. </p><p><i>Ankylosing spondylitis </i>should not be treated
with long-term <span>corticosteroids</span>; rarely, pulse doses
may be needed and may be useful in extremely active disease that does
not respond to conventional treatment.</p></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5269.htm">Previous: 10.1.2 Corticosteroids</a> | <a class="top" href="5270.htm#">Top</a> | <a accesskey="]" href="5272.htm">Next: 10.1.2.2 Local corticosteroid injections</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>